Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2025-10-27 Governance Information
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Amended Constitution 73 pages 1.5MB
Governance Information Classification · 100% confidence The document is titled 'Amended Constitution' and includes detailed sections of the company's constitution under the Corporations Act 2001. It references shareholder approval at the Annual General Meeting and provides the full text of the amended constitution, including detailed governance provisions such as share capital, meetings, and procedures. The content is a formal governance document rather than a financial report, earnings release, or announcement of voting results. It is not a brief announcement but a substantive document containing the company's internal rules and governance structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text, not just an announcement of publication.
2025-10-27 English
Chair Address and CEO AGM Presentation 20 pages 1.4MB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting' and includes a Chair's Address and CEO Presentation dated 14 October 2025. It discusses clinical progress, regulatory milestones, financial strength, leadership changes, strategic partnerships, and future outlook. The content is typical of materials presented at an AGM, including strategic updates and shareholder communications. There is no detailed financial statement or comprehensive annual financial data that would classify it as an Annual Report (10-K) or Interim Report (IR). The document is lengthy (15,000 characters) and contains the full text of the AGM presentation, not just an announcement of the meeting or report publication. Therefore, the document fits best into the category of AGM Information (AGM-R).
2025-10-13 English
Results of Annual General Meeting 3 pages 240.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is dated 14 October 2025 and is addressed to the ASX Limited Market Announcements Office. It is titled 'RESULTS OF 2025 ANNUAL GENERAL MEETING' and provides detailed voting results for resolutions passed at the 2025 Annual General Meeting (AGM) of Prescient Therapeutics Limited. The content includes proxy votes, poll results, and outcomes for various resolutions such as adoption of remuneration report, re-election and election of directors, approval of option issues, ratification of prior share issues, approval of placement facilities, and amendments to the company constitution. The document is a formal announcement of the voting results from the AGM, not the AGM materials themselves or the full annual report. It complies with regulatory requirements under the Corporations Act and ASX Listing Rules for disclosure of voting outcomes. The document length is 4703 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-13 English
September Quarterly Updated and Appendix 4C 10 pages 256.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'September 2025 Activities Report and Appendix 4C' and includes detailed quarterly financial information such as cash balances, capital raises, operating cash outflows, and clinical trial progress. It references the Appendix 4C quarterly cash flow statement, which is a regulatory requirement for quarterly reporting by entities listed on the ASX (Australian Securities Exchange). The document contains substantive financial data and analysis for the quarter ended 30 September 2025, including cash flow details and operational highlights. It is not merely an announcement of a report but contains the actual financial and operational data for the quarter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2025-10-09 English
Notice of Annual General Meeting/Proxy Form 28 pages 1.0MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting Explanatory Statement and Proxy Form' for Prescient Therapeutics Limited, with detailed information about the AGM date, time, location (hybrid meeting), registration instructions, agenda items including ordinary and special business resolutions, proxy voting instructions, and voting procedures. It includes resolutions related to adoption of the Remuneration Report, re-election and election of directors, approval of option grants, ratification of prior share issues, approval of a placement facility, and amendments to the company constitution. The document is clearly a notice and explanatory statement for an upcoming Annual General Meeting, not the actual meeting minutes, transcript, or financial report. It is a formal communication to shareholders to inform them about the AGM and solicit their votes via proxy or attendance. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and proxy forms. The document length (15,000 characters) is consistent with a detailed AGM notice and explanatory statement. Therefore, the correct classification is AGM Information (AGM-R).
2025-09-11 English
Notification regarding unquoted securities - PTX 6 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options by Prescient Therapeutics Limited. It includes specifics about the securities issued, their terms, and references to a previous Appendix 3B announcement. The content is a formal notification of securities issuance rather than a financial report, earnings release, or management discussion. This type of document corresponds to announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of capital changes.
2025-08-31 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.